|
1.
|
|
25 p, 635.6 KB |
CD34 + Cell Selection versus Reduced-Intensity Conditioning and Unmodified Grafts for Allogeneic Hematopoietic Cell Transplantation in Patients Age >50 Years with Acute Myelogenous Leukemia and Myelodysplastic Syndrome
/
Barba, Pere (Hospital Universitari Vall d'Hebron) ;
Martino Bofarull, Rodrigo (Institut d'Investigació Biomèdica Sant Pau) ;
Zhou, Qin (Memorial Sloan Kettering Cancer Center) ;
Cho, Christina (Weill Cornell Medical College) ;
Castro-Malaspina, Hugo (Weill Cornell Medical College) ;
Devlin, Sean M (Memorial Sloan Kettering Cancer Center) ;
Esquirol, Albert (Institut d'Investigació Biomèdica Sant Pau) ;
Giralt, Sergio (Weill Cornell Medical College) ;
Jakubowski, Ann A. (Weill Cornell Medical College) ;
Caballero, Dolores (Hospital Universitario Salamanca (CAUSA/IBSAL)) ;
Maloy, Molly (Memorial Sloan Kettering Cancer Center) ;
Papadopoulos, Esperanza B. (Weill Cornell Medical College) ;
Piñana, José Luis (Hospital Clínic Universitari (València)) ;
Fox, Maria Laura (Hospital Universitari Vall d'Hebron) ;
Márquez-Malaver, Francisco J. (Hospital Virgen del Rocío Sevilla) ;
Valcárcel, David (Hospital Universitari Vall d'Hebron) ;
Solano, Carlos (Hospital Clínic Universitari (València)) ;
López-Corral, Lucía (Hospital Universitario Salamanca (CAUSA/IBSAL)) ;
Malouf Sierra, Jorge 1971- (Institut d'Investigació Biomèdica Sant Pau) ;
Perales, Miguel-Angel (Weill Cornell Medical College) ;
Universitat Autònoma de Barcelona
Reduced-intensity conditioning (RIC) and T cell depletion (TCD) through CD34 cell selection without the use of post-transplantation immunosuppression are 2 strategies used to reduce nonrelapse mortality (NRM) in older patients after allogeneic hematopoietic cell transplantation (allo-HCT). [...]
2018 -  10.1016/j.bbmt.2017.12.804
Biology of blood and marrow transplantation, Vol. 24 Núm. 5 (may 2018) , p. 964-972
|
|
|
2.
|
|
10 p, 971.5 KB |
Comparison of High Doses of Total Body Irradiation in Myeloablative Conditioning before Hematopoietic Cell Transplantation
/
Sabloff, Mitchell (University of Ottawa and Ottawa Hospital Research Institute) ;
Chhabra, Saurabh (Medical College of Wisconsin) ;
Wang, Tao (Medical College of Wisconsin) ;
Fretham, Caitrin (National Marrow Donor Program/Be the Match) ;
Kekre, Natasha (The Ottawa Hospital Blood and Marrow Transplant Program and the Ottawa Hospital Research Institute) ;
Abraham, Allistair (Children's National Medical Center) ;
Adekola, Kehinde (Northwestern University) ;
Auletta, Jeffery J. (Nationwide Children's Hospital) ;
Barker, Christopher (Memorial Sloan Kettering Cancer Center) ;
Beitinjaneh, Amer (University of Miami) ;
Bredeson, Christopher (The Ottawa Hospital Blood and Marrow Transplant Program and the Ottawa Hospital Research Institute) ;
Cahn, Jean-Yves (CHU Grenoble Alpes) ;
Diaz, Miguel Angel (Hospital Infantil Universitario Niño Jesus) ;
Freytes, Cesar (Texas Transplant Institute) ;
Gale, Robert Peter (Imperial College London) ;
Ganguly, Siddhartha (University of Kansas Health System) ;
Gergis, Usama (New York Presbyterian Hospital/Weill Cornell Medical Center) ;
Guinan, Eva (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica)) ;
Hamilton, Betty K. (Cleveland Clinic Taussig Cancer Institute) ;
Hashmi, Shahrukh (King Faisal Specialist Hospital and Research Centre (Aràbia Saudita)) ;
Hematti, Peiman (University of Wisconsin) ;
Hildebrandt, Gerhard (University of Kentucky) ;
Holmberg, Leona (Fred Hutchinson Cancer Research Center) ;
Hong, Sanghee (Cleveland Clinic Taussig Cancer Center) ;
Lazarus, Hillard M. (Case Western Reserve University) ;
Martino Bofarull, Rodrigo (Institut d'Investigació Biomèdica Sant Pau) ;
Muffly, Lori (Stanford University) ;
Nishihori, Taiga (H. Lee Moffitt Cancer Center and Research Institute) ;
Perales, Miguel-Angel (Memorial Sloan Kettering Cancer Center) ;
Yared, Jean (University of Maryland) ;
Mineishi, Shin (Penn State Hershey Medical Center) ;
Stadtmauer, Edward A. (University of Pennsylvania Medical Center) ;
Pasquini, Marcelo (Medical College of Wisconsin) ;
Loren, Alison W. (Perelman School of Medicine at the University of Pennsylvania) ;
Universitat Autònoma de Barcelona
Malignancy relapse is the most common cause of treatment failure among recipients of hematopoietic cell transplantation (HCT). Conditioning dose intensity can reduce disease relapse but is offset by toxicities. [...]
2019 - 10.1016/j.bbmt.2019.08.012
Biology of blood and marrow transplantation, Vol. 25 Núm. 12 (december 2019) , p. 2398-2407
|
|
|
3.
|
|
10 p, 680.7 KB |
Lower Graft-versus-Host Disease and Relapse Risk in Post-Transplant Cyclophosphamide-Based Haploidentical versus Matched Sibling Donor Reduced-Intensity Conditioning Transplant for Hodgkin Lymphoma
/
Ahmed, Sairah (University of Texas) ;
Kanakry, Jennifer A. (National Institutes of Health (Bethesda, Estats Units d'Amèrica)) ;
Ahn, Kwang Woo (Medical College of Wisconsin) ;
Litovich, Carlos Alejandro (Medical College of Wisconsin) ;
Abdel-Azim, Hisham (University of Southern California Keck School of Medicine) ;
Aljurf, Mahmoud Deeb (King Faisal Specialist Hospital and Research Centre (Aràbia Saudita)) ;
Bacher, Vera Ulrike (Inselspital. Bern University Hospital) ;
Bejanyan, Nelli (Immunotherapy. Moffitt Cancer Center) ;
Cohen, Jonathon B. (Emory University School of Medicine) ;
Farooq, Umar (University of Iowa Hospitals and Clinics) ;
Fuchs, Ephraim Joseph (The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins) ;
Bolaños-Meade, Javier (The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins) ;
Ghosh, Nilanjan S. (Levine Cancer Institute. Atrium Health) ;
Herrera, Alex F. (City of Hope National Medical Center) ;
Hossain, Nasheed (Loyola University Chicago-Stritch School of Medicine) ;
Inwards, David (Mayo Clinic) ;
Kanate, Abraham Sebastian (West Virginia University) ;
Martino Bofarull, Rodrigo (Institut d'Investigació Biomèdica Sant Pau) ;
Munshi, Pashna (Georgetown University Hospital) ;
Murthy, Hemant S. (University Florida College of Medicine) ;
Mussetti, Alberto (Institut Català d'Oncologia-Hospitalet) ;
Nieto, Yago (University of Texas) ;
Perales, Miguel-Angel (Memorial Sloan Kettering Cancer Center) ;
Romee, Rizwan (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica)) ;
Savani, Bipin N. (Vanderbilt University Medical Center) ;
Seo, Sachiko (Dokkyo Medical University) ;
Wirk, Baldeep Mona (Seattle Cancer Care Alliance) ;
Yared, Jean A. (University of Maryland) ;
Sureda, Anna (Institut Català d'Oncologia-Hospitalet) ;
Fenske, Timothy S. (Medical College of Wisconsin) ;
Hamadani, Mehdi (Medical College of Wisconsin) ;
Universitat Autònoma de Barcelona
Classic Hodgkin lymphoma (cHL) patients with relapsed or refractory disease may benefit from allogeneic hematopoietic cell transplantation (allo-HCT), but many lack a matched sibling donor (MSD). Herein, we compare outcomes of 2 reduced-intensity conditioning (RIC) HCT platforms in cHL: T cell-replete related donor haploidentical (haplo) HCT with a post-transplant cyclophosphamide (PTCy)-based approach versus an MSD/calcineurin inhibitor (CNI)-based approach. [...]
2019 - 10.1016/j.bbmt.2019.05.025
Biology of blood and marrow transplantation, Vol. 25 Núm. 9 (september 2019) , p. 1859-1868
|
|
|
4.
|
|
10 p, 523.7 KB |
Risk Factors for Graft-versus-Host Disease in Haploidentical Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide
/
Im, Annie (University of Pittsburgh/UPMC Hillman Cancer Center) ;
Rashidi, Armin (University of Minnesota) ;
Wang, Tao (Medical College of Wisconsin) ;
Hemmer, Michael (Medical College of Wisconsin) ;
MacMillan, Margaret L. (University of Minnesota) ;
Pidala, Joseph (H. Lee Moffitt Cancer Center and Research Institute) ;
Jagasia, Madan (Vanderbilt University Medical Center) ;
Pavletic, Steven (National Cancer Institute of Bethesda) ;
Majhail, Navneet S. (Cleveland Clinic Taussig Cancer Institute) ;
Weisdorf, Daniel (University of Minnesota) ;
Abdel-Azim, Hisham (University of Southern California Keck School of Medicine) ;
Agrawal, Vaibhav (Indiana University School of Medicine) ;
Al-Homsi, A.Samer (New York University Langone Medical Center) ;
Aljurf, Mahmoud (King Faisal Specialist Hospital and Research Centre (Aràbia Saudita)) ;
Askar, Medhat (Baylor University Medical Center) ;
Auletta, Jeffery J (Nationwide Children's Hospital) ;
Bashey, Asad (Blood and Marrow Transplant Program at Northside Hospital) ;
Beitinjaneh, Amer (University of Miami) ;
Bhatt, Vijaya Raj (University of Nebraska Medical Center) ;
Byrne, Michael (Vanderbilt University Medical Center) ;
Cahn, Jean-Yves (CHU Grenoble Alpes) ;
Cairo, Mitchell S (New York Medical College) ;
Castillo, Paul (UF Health Shands Children's Hospital) ;
Cerny, Jan (University of Massachusetts Medical Center) ;
Chhabra, Saurabh (Medical College of Wisconsin) ;
Choe, Hannah (The Ohio State University Wexner Medical Center) ;
Ciurea, Stefan (The University of Texas MD Anderson Cancer Center) ;
Daly, Andrew (Tom Baker Cancer Center) ;
Perez, Miguel Angel Diaz (Hospital Infantil Universitario Nino Jesus) ;
Farhadfar, Nosha (University of Florida College of Medicine) ;
Gadalla, Shahinaz M. (NIH-NCI Clinical Genetics Branch) ;
Gale, Robert (Imperial College London) ;
Ganguly, Siddhartha (University of Kansas Health System) ;
Gergis, Usama (Thomas Jefferson University) ;
Hanna, Rabi (Cleveland Clinic Foundation) ;
Hematti, Peiman (University of Wisconsin) ;
Herzig, Roger (University of Kentucky Chandler Medical Center) ;
Hildebrandt, Gerhard C. (University of Kentucky) ;
Lad, Deepesh P. (Postgraduate Institute of Medical Education and Research) ;
Lee, Catherine (University of Utah) ;
Lehmann, Leslie (Dana-Farber Cancer Institute/Boston Children's Hospital) ;
Lekakis, Lazaros (University of Miami) ;
Kamble, Rammurti T. (Baylor College of Medicine) ;
Kharfan-Dabaja, Momamed A. (Mayo Clinic) ;
Khandelwal, Pooja (University of Cincinnati) ;
Martino Bofarull, Rodrigo (Institut d'Investigació Biomèdica Sant Pau) ;
Murthy, Hemant S. (Mayo Clinic) ;
Nishihori, Taiga (Moffitt Cancer Center) ;
O'Brien, Tracey A. (Sydney Children's Hospital) ;
Olsson, Richard F. (Uppsala University) ;
Patel, Sagar S. (University of Utah) ;
Perales, Miguel-Angel (Memorial Sloan Kettering Cancer Center) ;
Prestidge, Tim (Starship Children's Hospital (Auckland, Nova Zelanda)) ;
Qayed, Muna (Emory University School of Medicine) ;
Romee, Rizwan (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica)) ;
Schoemans, Hélène (University Hospitals Leuven (Bèlgica)) ;
Seo, Sachiko (Dokkyo Medical University) ;
Sharma, Akshay (St. Jude Children's Research Hospital (Memphis, Estats Units d'Amèrica)) ;
Solh, Melhem (Northside Hospital) ;
Strair, Roger (Rutgers University) ;
Teshima, Takanori (Hokkaido University Hospital) ;
Urbano-Ispizua, Alvaro (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Van der Poel, Marjolein (Maastricht University Medical Center) ;
Vij, Ravi (Washington University School of Medicine) ;
Wagner, John L. (Thomas Jefferson University) ;
William, Basem (The Ohio State University) ;
Wirk, Baldeep (Penn State Cancer Institute) ;
Yared, Jean A. (University of Maryland) ;
Spellman, Steve R. (Medical College of Wisconsin) ;
Arora, Mukta (University of Minnesota Medical Center) ;
Hamilton, Betty K. (Cleveland Clinic Taussig Cancer Institute) ;
Universitat Autònoma de Barcelona
Post-transplant cyclophosphamide (PTCy) has significantly increased the successful use of haploidentical donors with a relatively low incidence of graft-versus-host disease (GVHD). Given its increasing use, we sought to determine risk factors for GVHD after haploidentical hematopoietic cell transplantation (haplo-HCT) using PTCy. [...]
2020 - 10.1016/j.bbmt.2020.05.001
Biology of blood and marrow transplantation, Vol. 26 Núm. 8 (august 2020) , p. 1459-1468
|
|
|
5.
|
|
8 p, 440.5 KB |
Standardizing Definitions of Hematopoietic Recovery, Graft Rejection, Graft Failure, Poor Graft Function, and Donor Chimerism in Allogeneic Hematopoietic Cell Transplantation : A Report on Behalf of the American Society for Transplantation and Cellular Therapy
/
Kharfan-Dabaja, Mohamed A. (Mayo Clinic. Division of Hematology-Oncology and Blood and Marrow Transplantation and Cellular Therapies Program) ;
Kumar, Ambuj (Program for Comparative Effectiveness Research. Morsani College of Medicine. University of South Florida) ;
Ayala, Ernesto (Division of Hematology-Oncology and Blood and Marrow Transplantation and Cellular Therapies Program. Mayo Clinic) ;
Aljurf, Mahmoud (Department of Adult Hematology and Stem Cell Transplantation. King Faisal Specialist Hospital and Research Centre) ;
Nishihori, Taiga (Department of Blood and Marrow Transplantation and Cellular Immunotherapy. Moffitt Cancer Center) ;
Marsh, Rebecca (Cincinnati Children's Hospital Medical Center) ;
Burroughs, Laura M. (Fred Hutchinson Cancer Research Center) ;
Majhail, Navneet (Blood and Marrow Transplant Program. Taussig Cancer Institute. Cleveland Clinic) ;
Al-Homsi, Ahmad Samer (NYU Langone Health) ;
Al-Kadhimi, Zaid S. (Division of Oncology and Hematology. Department of Internal Medicine. University of Nebraska Medical Center) ;
Bar, Merav (Fred Hutchinson Cancer Research Center) ;
Bertaina, Alice (Division of Stem Cell Transplant and Regenerative Medicine. Department of Pediatrics. Stanford University) ;
Boelens, Jaap Jan (Stem Cell Transplantation and Cellular Therapies Program. Department Pediatrics. Memorial Sloan Kettering Cancer Center) ;
Champlin, Richard (Department of Stem Cell Transplantation and Cellular Therapy. The University of Texas MD Anderson Cancer Center) ;
Chaudhury, Sonali (Ann and Robert H. Lurie Children's Hospital of Chicago) ;
DeFilipp, Zachariah (Department of Hematology-Oncology and Hematopoietic Cell Transplant and Cellular Therapy Program. Massachusetts General Hospital) ;
Dholaria, Bhagirathbhai (Vanderbilt University Medical Center) ;
El-Jawahri, Areej (Department of Hematology-Oncology and Hematopoietic Cell Transplant and Cellular Therapy Program. Massachusetts General Hospital) ;
Fanning, Suzanne (Blood and Marrow Transplant Program. University of South Carolina School of Medicine) ;
Fraint, Ellen (Stem Cell Transplantation and Cellular Therapies Program. Department Pediatrics. Memorial Sloan Kettering Cancer Center) ;
Gergis, Usama (Bone Marrow Transplant and Immune Cellular Therapy. Thomas Jefferson University Hospital) ;
Giralt, Sergio (Department of Medicine. Division of Hematologic Malignancies. Memorial Sloan Kettering Cancer Center Weill Cornell Medical College) ;
Hamilton, Betty K. (Blood and Marrow Transplant Program. Taussig Cancer Institute. Cleveland Clinic) ;
Hashmi, Shahrukh K (Department of Medicine. Sheikh Shakhbout Medical City) ;
Horn, Biljana (Department of Pediatrics. Division of Hematology/Oncology. University of Florida. UF Health Shands Children's Hospital) ;
Inamoto, Yoshihiro (National Cancer Center Hospital) ;
Jacobsohn, David A. (Children's National Medical Center) ;
Jain, Tania (Johns Hopkins University School of Medicine) ;
Johnston, Laura (Stanford University School of Medicine) ;
Kanate, Abraham S. (West Virginia University) ;
Kansagra, Ankit (UT Southwestern Medical Center) ;
Kassim, Adetola (Vanderbilt University Medical Center) ;
Kean, Leslie S. (Boston Children's Hospital. Dana-Farber Cancer Institute) ;
Kitko, Carrie L. (Vanderbilt University Medical Center) ;
Knight-Perry, Jessica (University of Colorado School of Medicine) ;
Kurtzberg, Joanne (Duke University School of Medicine) ;
Liu, Hien (Moffitt Cancer Center) ;
MacMillan, Margaret L (University of Minnesota Medical School) ;
Mahmoudjafari, Zahra (University of Kansas Cancer Center) ;
Mielcarek, Marco (Fred Hutchinson Cancer Research Center) ;
Mohty, Mohamad (Sorbonne Université. INSERM. Centre de Recherche Saint-Antoine and Hôpital Saint-Antoine. Service d'Hématologie Clinique et Thérapie Cellulaire) ;
Nagler, Arnon (Chaim Sheba Medical Center (Israel)) ;
Nemecek, Eneida (Oregon Health & Science University) ;
Olson, Timothy S. (Children's Hospital of Philadelphia (Pennsilvània)) ;
Oran, Betul (The University of Texas MD Anderson Cancer Center) ;
Perales, Miguel Angel (Memorial Sloan Kettering Cancer Center Weill Cornell Medical College) ;
Prockop, Susan E. (Stem Cell Transplantation and Cellular Therapies Program. Department Pediatrics. Memorial Sloan Kettering Cancer Center) ;
Pulsipher, Michael A. (Children's Hospital Los Angeles Cancer and Blood Disease Institute. USC Keck School of Medicine) ;
Pusic, Iskra (Washington University School of Medicine) ;
Riches, Marcie L. (University of North Carolina at Chapel Hill) ;
Rodriguez, Cesar (Wake Forest University School of Medicine) ;
Romee, Rizwan (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica)) ;
Rondon, Gabriela (The University of Texas MD Anderson Cancer Center) ;
Saad, Ayman (The Ohio State University. Division of Hematology) ;
Shah, Nina (University of California San Francisco. Department of Medicine) ;
Shaw, Peter J. (The Children's Hospital at Westmead) ;
Shenoy, Shalini (Washington University School of Medicine) ;
Sierra, Jorge (Institut d'Investigació Biomèdica Sant Pau) ;
Talano, Julie (Children's Hospital of Wisconsin) ;
Verneris, Michael R. (University of Colorado School of Medicine) ;
Veys, Paul (University College London. Great Ormond Street Hospital.) ;
Wagner, John E. (University of Minnesota Medical School) ;
Savani, Bipin N. (Vanderbilt University Medical Center) ;
Hamadani, Mehdi (Medical College of Wisconsin) ;
Carpenter, Paul A. (Fred Hutchinson Cancer Research Center) ;
Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras ;
Universitat Autònoma de Barcelona.
Departament de Medicina
Allogeneic hematopoietic cell transplantation (allo-HCT) is potentially curative for certain hematologic malignancies and nonmalignant diseases. The field of allo-HCT has witnessed significant advances, including broadening indications for transplantation, availability of alternative donor sources, less toxic preparative regimens, new cell manipulation techniques, and novel GVHD prevention methods, all of which have expanded the applicability of the procedure. [...]
2021 - 10.1016/j.jtct.2021.04.007
Transplantation and Cellular Therapy, Vol. 27 Núm. 8 (august 2021) , p. 642-649
|
|
|
6.
|
|
|
7.
|
|
21 p, 278.8 KB |
Long-term prognosis for 1-year relapse-free survivors of CD34 cell-selected allogeneic hematopoietic stem cell transplantation : a landmark analysis
/
Cho, Christina (Weill Cornell Medical College, New York, NY, 10065, USA) ;
Hsu, Meier (Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA) ;
Barba, Pere (Hospital Universitari Vall d'Hebron) ;
Maloy, Molly A. (Memorial Sloan Kettering Cancer Center) ;
Avecilla, Scott T. (Department of Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA) ;
Barker, Juliet N. (Weill Cornell Medical College, New York, NY, 10065, USA) ;
Castro-Malaspina, Hugo (Weill Cornell Medical College, New York, NY, 10065, USA) ;
Giralt, Sergio A. (Weill Cornell Medical College, New York, NY, 10065, USA) ;
Jakubowski, Ann A. (Weill Cornell Medical College, New York, NY, 10065, USA) ;
Koehne, Guenther (Weill Cornell Medical College, New York, NY, 10065, USA) ;
Meagher, Richard C. (Department of Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA) ;
O'Reilly, Richard J. (Memorial Sloan Kettering Cancer Center) ;
Papadopoulos, Esperanza B. (Weill Cornell Medical College, New York, NY, 10065, USA) ;
Ponce, Doris M. (Weill Cornell Medical College, New York, NY, 10065, USA) ;
Tamari, Roni (Weill Cornell Medical College, New York, NY, 10065, USA) ;
van den Brink, Marcel R. M. (Weill Cornell Medical College, New York, NY, 10065, USA) ;
Young, James W. (The Rockefeller University, New York, NY, 10065, USA) ;
Devlin, Sean M. (Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA) ;
Perales, Miguel-Angel (Weill Cornell Medical College, New York, NY, 10065, USA) ;
Universitat Autònoma de Barcelona
CD34 selection significantly improves GVHD-free survival in allogeneic hematopoietic cell transplantation (allo-HSCT). Specific information regarding long-term prognosis and risk factors for late mortality after CD34-selected allo-HSCT is lacking, however. [...]
2017 - 10.1038/bmt.2017.197
Bone marrow transplantation, Vol. 52 (october 2017) , p. 1629-1636
|
|
visitant ::
identificació
alerta personal via correu electrònic o subscribiu-vos al 
canal RSS.
